We are pleased to announce that EXCAAPE study “A phase II clinical trial of radium-223 activity in patients with metastatic castration-resistant prostate cancer (mCRPC) with asymptomatic progression while on abiraterone acetate or enzalutamide besides AR-V7 mutational status” has achieved 100% of recruitment!
9 Spanish sites have participated and a total of 63 patients have been recruited (52 treated and 11 Screening Failure) since December 2016. It’s been a long journey with many difficulties but the perseverance and effort of the site investigators and collaborators have been the main key to achieve it.
From the MedSIR team, we would like to thank all the study teams for their implication and effort identifying patients, who can benefit from their participation. In special, we would like to thank to Hospital Vall Hebrón (Dr Joan Carles Galcerán), Hospital Ramón y Cajal (Dr Teresa Alonso) and Hospital Clínic de Barcelona (Dr Begoña Mellado) for their commitment and for being the top recruiters. Other special thanks to Bayer for their continuous support during the conduct of the trial.